State Law on Prescribing Opioids for Chronic Non-Cancerous Pain
Summary of recent (2018) changes in opioid prescribing regulations in Mississippi
- Review the Mississippi Prescription Monitoring Program database (MPMP) prior to each outpatient opioid or benzodiazepine prescription. Note: The MPMP does not include controlled substances administered in a clinic, inpatient, or emergency department setting.
- Document review of the MPMP in the patient’s chart upon initial controlled substance prescription and at least every 3 months thereafter (exceptions include: amphetamines for patients <16 y/o, Lomotil®, Lyrica®, pseudoephedrine, and testosterone).
- Order point of service drug testing 3 times per year if prescribing Schedule II opioids for chronic non-cancerous/non-terminal pain, or benzodiazepines for chronic psychiatric or medical conditions.
- Limit each prescription for acute pain opioid treatment to 3-10 days.
- Strive to keep opioid total below 50 Morphine Milligram Equivalent (MME)/day and avoid 90 MME/day or greater for chronic non-cancerous/non-terminal pain.
- Refer patient for a consultation with a pain specialist if 100 MME/day or greater is indicated for chronic non-cancerous/non-terminal pain in order to verify or optimize the current treatment plan.
- Avoid prescribing benzodiazepines, opioids and/or carisoprodol together.
Click here for a PDF regarding Mississippi law.